<SEC-DOCUMENT>0001493152-18-003311.txt : 20180314
<SEC-HEADER>0001493152-18-003311.hdr.sgml : 20180314
<ACCEPTANCE-DATETIME>20180314084618
ACCESSION NUMBER:		0001493152-18-003311
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180314
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180314
DATE AS OF CHANGE:		20180314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Propanc Biopharma, Inc.
		CENTRAL INDEX KEY:			0001517681
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300662986
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54878
		FILM NUMBER:		18688390

	BUSINESS ADDRESS:	
		STREET 1:		302/6 BUTLER STREET
		CITY:			CAMBERWELL, VICTORIA
		STATE:			C3
		ZIP:			3124
		BUSINESS PHONE:		613-9882-6723

	MAIL ADDRESS:	
		STREET 1:		302/6 BUTLER STREET
		CITY:			CAMBERWELL, VICTORIA
		STATE:			C3
		ZIP:			3124

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Propanc Health Group Corp
		DATE OF NAME CHANGE:	20110408
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
of Report (Date of earliest event reported): March 14, 2018</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B><U>PROPANC
BIOPHARMA, INC.</U></B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 32%; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 32%; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-54878</B></FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 32%; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>33-0662986</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
        or other Jurisdiction</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
        Incorporation)</FONT></P></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
        Number)</FONT></P></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
        Employer</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
        No.)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 66%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>302,
        6 Butler Street</B></FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Camberwell,
        VIC, 3124 Australia</B></FONT></P></TD>
    <TD STYLE="width: 2%; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of Principal Executive Offices)</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s
telephone number, including area code: <B>61 03 9882 6723</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report.)</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company &#9;[&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    7.01</B></FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
    FD Disclosure</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 14, 2018, Propanc Biopharma, Inc. (the &ldquo;Company&rdquo;) announced the successful reproduction run of the manufacturing
process for the Company&rsquo;s two drug substances typsinogen and chymotrypsinogen.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
press release relating to such event is attached as Exhibit 99.1 hereto.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes of
Section 18 of the Securities and Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise be subject to
the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    9.01</B></FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibits</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 0.5in; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Exhibit</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 0.2in; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">99.1</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Press Release, dated as of March 14, 2018</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Propanc Biopharma, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 14, 2018</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    James Nathanielsz</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Nathanielsz</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, Chief Financial Officer and Chief Accounting Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Propanc
Biopharma Completes Successful Reproduction Run for PRP</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Company
Requests Scientific Advice Meeting with the MHRA (UK) to Discuss Next Steps</I></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MELBOURNE,
AUSTRALIA, March 14, 2018</B>-- <U>Propanc Biopharma Inc</U>. (OTCQB: PPCB) (&ldquo;Propanc Biopharma&rdquo; or the &ldquo;Company&rdquo;),
a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering
from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the successful reproduction run of the manufacturing
process for the Company&rsquo;s two drug substances trypsinogen and chymotrypsinogen. The successful reproduction run demonstrates
scalability of Propanc&acute;s proprietary manufacturing process to enable routine production of the two active substances for
the Company&rsquo;s lead product candidate, PRP. The process was developed in collaboration with a European Contract Manufacturing
Organization (CMO) experienced in the production of biopharmaceuticals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the successful reproduction run, a scientific advice meeting was requested with the UK Medicines and Healthcare Products
Regulatory Agency (MHRA) to inform them of the results from recent manufacturing activities and confirm requirements for the next
stage of GMP manufacture for PRP. Given the unique potential of these active biological drug substances, management continues
to engage in proactive communication with the regulators to advance the product candidate towards clinical and market approval.</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
are delighted with the results from the reproduction run, which shows that the proprietary process is scalable and robust so that
we can produce our drug substances, routinely,&rdquo; said James Nathanielsz, Propanc Biopharma&rsquo;s Chief Executive Officer.
&ldquo;As a result, the Company requested a scientific advice meeting with the MHRA to update the agency about our progress.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
Propanc management team continues to remain focused and diligent regarding the advancement of PRP into clinical trials,&rdquo;
said Professor Klaus Kutz, Propanc Biopharma&rsquo;s Chief Medical Officer. &ldquo;Our regulatory and development team are working
hard to ensure we have good communication with the MHRA.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRP
is a proposed solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and
chymotrypsinogen. Currently progressing towards a First-In-Human study, PRP aims to prevent tumor recurrence and metastasis from
solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According
to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative
therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company&rsquo;s
initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment
of $14 billion in 2020, according to GBI Research.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
view Propanc Biopharma&rsquo;s &ldquo;Mechanism of Action&rdquo; video on anti-cancer product candidate, PRP, please click on
the following link: <U>http://www.propanc.com/news-media/video</U></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be added to Propanc Biopharma&rsquo;s email distribution list, please click on the following link: <U>http://ir.propanc.com/email-alerts
</U>and submit the online request form.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Propanc Biopharma:</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Propanc
Biopharma is a clinical stage biopharmaceutical company developing new cancer treatments initially for patients suffering from
pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of
effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ
pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with limited remaining
therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product candidate to treat (i)
early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer
based on genetic screening. For more information, visit: <U>www.propanc.com.</U></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements:</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
statements other than statements of historical fact contained herein are &ldquo;forward-looking statements&rdquo; for purposes
of federal and state securities laws. Forward-looking statements may include the words &ldquo;may,&rdquo; &ldquo;will,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;intend,&rdquo; &ldquo;continue,&rdquo; &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan&rdquo;
or &ldquo;anticipate&rdquo; and other similar words. Although we believe that the expectations reflected in our forward-looking
statements are reasonable, actual results could differ materially from those projected or assumed. Our future financial condition
and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties
including those regarding our earnings, revenues and financial condition, our ability to implement our plans, strategies and objectives
for future operations, our ability to execute on proposed new products, services or development thereof, our ability to establish
and maintain the proprietary nature of our technology through the patent process, our ability to license from others patents and
patent applications, if necessary, to develop certain products, our ability to implement our long range business plan for various
applications of our technology, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution
partners for purposes of commercialization, the results of our clinical research and development, competition in the industry
in which we operate, overall market conditions, and any statements or assumptions underlying any of the foregoing. Other risks,
uncertainties and factors that could cause actual results to differ materially from those projected may be described from time
to time in reports we file with the Securities and Exchange Commission, including our reports on Forms 10-K, 10-Q and 8-K. We
do not intend, and undertake no obligation, to update any forward-looking statement contained herein, except as required by law.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media
Contact:</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Parker
Mitchell</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>parkeramitchell@gmail.com</U></FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !# /L# 2(  A$! Q$!_\0
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M033LX\>6XC)8X?$3Q#P$ZF+K<R]GS3DU-J,4_:4XM3O+W4FTY.-W:[/YV/\
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M7QGT;4/$$D<1^58-)U7X;Z!HKWTZC%K;_P#"020RSO&CS)&Q<?G!_P $6O\
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MM);A&M!XG^&VL>&K31M:>"';+)>0:=XM\1::&@EA-XE\@NC-+9:=):?U2?\
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MJD8LX4M].B>X%AIEI=22RZCJ5_:H8-*TZUCO)=:NY(K>S:W>5!7\"Z_L&?\
M!9+_ ()B?%*]\9? 3P7\5[N ZU=K8>+?@)=6'Q+\*^+-+AO+VQT";Q-X2LK?
M4;&_UN2QNFM)]&U_P&%ABDCLK2^LX(;62#8\7_LS?\%T/^"I?B'1K7XQ^#?B
M[J&BZ!<"&SU/XLZ7X;^!/PI\.275U$]U<3^!M-'@Z\U*^MV N;FXL-)N[V1(
MF6V221EC;]<S[PHX6S[/<RXJ_P!?>%J?"O$68PQN9X;%9ABEG5&,ZU*>)HT:
M$,+5PG-[/VL:;EBZ;4G%3INVODT,;4C?+Z6#QD*T(M>TE3A&CL]>93<VDW>[
MALGTLC@_V8K;7?\ @I#_ ,%K-"^+/@WPWK$_@WQ1^T]<_M#>)8[Y+I?^$5^&
M?@?6[;Q/8C4!$8[BSO)_#>C>$_"$]G/(L$6NZHL4$*^;=F7F/^"U/QL@^,7_
M  53^,VK:]--K'@SX3^-O!WPDTG3K&82W)\/?#O3[.+Q39V\R$20K<^)I/'R
MR,)?,6X)Q*JL@7^N?]C[]B+X/?\ !'#]COXV?%R?5;CQ=\3-'^%GB'XE?&GX
MF:W:N[:I-\/?#^KZTWAOP];HZ76E>'+75(V%X #?>)62SNKR6]N;:P:R_CO_
M ."='[)6O?\ !4[]LWXDZ1\3-2UK1=/\3>$/CE\9/B/XITM+>+4M!\7^.8M4
MB\-:C-<0I:V,-AIWQ+UZSUA=,/D&ZLK*\L'']FRW%NWZ1PWQ7DN?9UQ-Q7*M
M4P_"7A]PNN!>'\7BX1C5K86MAZN78C$0C3G4C*V#Q%9TFJO/+W&XIG)7PF)H
M4'EUX5,;C*T<3"=-MTN2G.-25.4G%2YY*,HQ2@XN<HIR4;M?Z,'P;^(O@3XH
M_"?P!\0?A;>V-_\ #;QCX6T'Q)X(U+1U@FTR3PQJ>E6MWI"HD'FC3KG3K.XC
MM[BVE!2R?3'A\M$5HA^6?_!<W]KWX:_L[_L(?&#X>:MXDTZS^*?[0WA+6?A#
M\.?"TUU$NN7S^,KA=&\0ZI>V.QKVV\/Z'H.H7FI7-^!'%+#&Q$H5=S?SAZ;\
M%_\ @O7_ ,$P+S6_A+\"=/\ C!XE^%>L:]KL/AO6?A5X$\,_&WPE?Z5#*+R+
M5- \/3>%OB/KGP\-U#;PQ7>FZUH/@RPP9(?#5A?K((IN3^#7_!)/_@J'_P %
M&/CMH?Q-_;)M_BMX$\(>(=3LA\0_BI\8M7TBV\8:3H%O?00ZCX>^'/PXU6]:
MZT+6-4TE[BSL4F\':3H$]W+;PZU:RV!FA/YAD_AMP5EN?4N,,UX[X;QO#&$Q
M-+,*>7T,9C/[=Q=/!UX8RG@Y49X18:G5Q*PL,,YTL9+GJU(\OLU.;I^C6QN,
MJX-X"CE^*IUY0=)RJ1I1A#GC*FY2<:CERQYW-^ZW%1;LVHIVO^"$&FZO\ -.
M_;E_X*$:MX-OM5\$_LQ?LI>--"T&.XBEM[76_B!>:K8^*U\-P7KHXN;BST_P
M+$^NW$JWB6NA^+M)NPAN5WCYK_8Q_9O^*_\ P6K_ &]O&%W\</B?/IES>Z#=
M_&?XL^+4@A;5;;P/9ZYH^EV/A3X8^'9+>XTG1I+ZX\4Z/HXUAK-(=!TVRN9=
M6TV\UN5)9/[K-&_8"^!'A#]B#Q'^PEX*L-7\-?"7Q-\,_%O@#5]5L[^6/QQ<
M77BS3M2L]9\9:GKES-)-?^(//OOMD=W<RRM%#:6&D0[=&L;6RA_B@TS]A7_@
MKG_P2N_:)F\<? /X7?$GQ!J6D?\ "4^&M$^)OPK\(Z1\2_A]\1O [WMJEWJF
MO^$]-M?&=UI)UBTMM.U#7].\::-8:C#K>G+XG-]93VZ:A%]UPUQQPUQ?C/%?
M.\IS#*.#^*L=A</E/ U7.FL3A\#ET(RPU:IB,15I8JK0QM.C.5>D\+1Q4H8J
M.'J6Y*?M%A4P-3+H9=RT:U;#P4%CHX>TI5:MXOF@I."E%N]G-QT6UW8_HB\<
M?\&ZW_!+GPQ\.]5U#Q$OQD\)P>%/#U_K?BKXFS_%R:*6VT[2;":\U'Q!XAMM
M;TBZ\"Z=::=;P27[6FG:+8F6"(K.)$,@K^1K]B7]G_P]^T+_ ,%*/@Y\)?@Z
MNL>*OA@G[2%OXBT#5?%$5AI^M+\'/ WB!_&>HZAXANH+ N\UWX$\+WFF2P:&
MFCV-QXGU/1M*0Q6UUY=?N5\0?A+_ ,%T?^"AOP#^(M_^U=I_B3X6?"71OA]K
MOC3P7\&?ASX5\$^%O&GQD^)<44]GX:^'Q\)Z7KU]X\C\/Q72VTFLW7C?4M.M
M+J&[N4\F&S,BIW?_  ;\_P#!/3]I/]FK]I#XS?&_]I/X*>+?A=%IGP@7PE\,
M]0\43Z)<WOB.Y\9^+-*U349M)L].U^_U&4Z?H_A;3(;^TN9I$,FO2PQA)VC(
M,JXBQ_"? WB#B<_\5H\1Y_FF5PR/+J>"S5XB7-.E4PU15YXK 8.?LYQQ3YG1
MYE&"E%>^AXBC2QF.I*.%Q5.BDJSG4A",(>S:J-3:J22?[NRNNNME<_.?_@XF
M^/MW\<?^"A5[\'/#IDOM+_9U\+^'_A?IMG\CI=^+_$VGV'B[Q*EG'&BF2\NY
M]=\,^'R&WF"XT$?95MY9[PS_ -NW[$?[.FE_LH_LI_ ?]GFQAM_/^&/PZT;P
M]JMW"K>7=^(Y5BUGQ7JL8E,@CEU+Q-JE]J$BQ;((Y%BAMXXK6TM8(?XV_AY_
MP38_;J_:2_X*LZ+\<OCG^S+\0O GPH\9?M6ZG\8?'7B_Q%::?;^'['PAX:^(
M5UXUTW2HD@U%-06'5M-T/1_"<+S&2<6E^DT6^X1)*_O'A^2)HTE$KHCLDS L
M9+AF,F[9E!AYCN*!T3&$!1 ,?F/BYG.3PX3\-N#,GS/#8G!8++99CF+P=1U$
M\ZKTK5Y.I![*3J-RJ1A-QY9.*4D:95"7M<77JRI/$5:\5A)JM3:IT)3BK3UY
MHNS^PIKL[VO_ !K_ /!U1\=-"F\1_LJ?LXVUX\FL:);^-OCMXLL 8I8+2VUB
MW_X0+PG=N"A*7%G;Z3X^6",%8G::"XDBDNDMYX[NN?LO_%/X5?\ !LC?Z+I^
MG7<'C'Q3K6@?'SXB:- FVZ7P)>_%[0M6F:6*5661+?P'I?A^_NXO+$4EH[K<
MH\$;J?'_ /@K;^P1^W%^V5_P4U\3>,?#/[.GQ USX+/-\'?A!H?CZWN/"=KH
MEI\/-,71+OQ3XO+S:L=2EM+?Q)?^,Y+B..*2X>VLV$4&+HPO_91XG^$G@K7O
MA%J?P3U71#-\-=4\#WGPRU+P^)_EE\!W_AN[\.7.DI>/*LL+#2?)B@U"6X6[
MMY8XK@W*3JTQ]?->(LNX1X&\),GRW%T,;'#9I#B;/,-1J0JN-6GB\/B84YKF
MLJT$I2<*BA&T&U*R=ZPV"Q&,Q=6O.E.C3Q57,,!1G67*G5P]*M%U'RJ5J%67
M*J4HWE)M)QCL?Q__ /!K1\0/AYIGQ8_:?^'NKZI:V7Q*\8>"? ?B?P;:WYB%
MYJ/A#PAJ?B>Q\0V'A[4$_>W-CH=W=:5]HMG-R9+.,EXY($<5_:1K&IZ?H]GJ
M&J:G/IVGV&G65UJ=_?ZK>0:;INGVMO#))<7M_J%RAMK.RCMXGDO+J6=?(MHY
M)VMV",M?P0?M+?\ !%K]OW]ACXY2_&7]AG2OB'\1?A]X,U2QUWX8^._A[?VD
M_P 5_#\)F?S=$U3PA9VEOK.I:;HEI(YA@L/"^K:7XDFBBN-7N]2N7%P><\;W
MG_!P;^WMHL/P)\?>"_VB;SPCK@C@UW2=8^%?A3X&^!M1MK5Q%)%XI\4MX>^'
MVCW\]S&6%\+SQ#KMS.KRO/X6UAMUA/Z''W!_#?B!Q'+CC)^-^&,%D_$.68%9
MKEN;X[%4LWP6,PZIRQ+AA,-A<5AE04%.4%4Q=.>B4J?++6L!B:F6T*F&GA<3
M7J4*D:4GAX0E!SE.,8R4ISIRY%)Q<I6345)I75C^_/PUKWA[Q?H^B^(O#&M:
M?XBT#5]/@OM%\0:1>6NH66HV%U&;FVN]/U*R#6DEK>06\D=Q' R^64C14BX8
M]B-N!\J'CJ5&:_+/_@DE^R#\8/V(?V/_  I\#?C-\1(_&GBNSUW6_$B:3IZ^
M?X8^'ND>(9GEC\#^&]2G@?5-1BL+^UGN9Y=4O[^"T:^>ST,6.GI#;#]2%9
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MY,D<NQX/$O!_["GB_P .:QHOB"Z\5^'X%UGX^^%_C'\0O!WA6SN/"?P_TY?
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MAQ:1!JWQ6T2'QAXSEU<>#_">O:=K5SX1>RN_#!BLY=7O;.ZU;2/M""PFC-I
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M9L_4N',5F6+RNC5S*CF=#$/XHUZ5"G)VOK95YM:6TO;?5Z&E1117&>Z%%%%
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MUUUYXZZK<M>6G/R]?4D\8 (&3P#M&5& 3R1DFHGMXB0Y#;E!P1+*.-ZR8.'
M(W*!@Y&PM%CRW=&**Y^2"^Q'_P !7^1"D[K5].K\O,KF)&<!EW#(.&)(+* 5
L9LD[F4JI5FR05!!! JZJ+@<=AW/^-%%;TF^5:O[W_F.O*7+'WGOW?9^9_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
